Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1985 Aug;52(2):153–158. doi: 10.1038/bjc.1985.171

Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.

I C MacLennan, J Cusick
PMCID: PMC1977102  PMID: 3896288

Abstract

In the Medical Research Council's IVth trial in Myelomatosis the possible benefit of adding vincristine to first line treatment with intermittent melphalan and prednisone has been assessed. This was analysed in 530 patients who were randomly allocated to receive vincristine or not. Survival was not improved by the addition of vincristine. A total of 268 patients reached plateau phase on first line therapy. Of these 226 patients were rerandomised either to continue receiving first line therapy for a further year or to cease therapy. At the present time there is a slight but not significant survival advantage in the group which received no further treatment on reaching plateau.

Full text

PDF
153

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexanian R., Dreicer R. Chemotherapy for multiple myeloma. Cancer. 1984 Feb 1;53(3):583–588. doi: 10.1002/1097-0142(19840201)53:3<583::aid-cncr2820530336>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  2. Alexanian R., Gehan E., Haut A., Saiki J., Weick J. Unmaintained remissions in multiple myeloma. Blood. 1978 Jun;51(6):1005–1011. [PubMed] [Google Scholar]
  3. Barlogie B., Smith L., Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984 May 24;310(21):1353–1356. doi: 10.1056/NEJM198405243102104. [DOI] [PubMed] [Google Scholar]
  4. Bonnet J. D., Alexanian R., Salmon S. E., Haut A., Dixon D. O. Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. Cancer Treat Rep. 1984 Mar;68(3):481–485. [PubMed] [Google Scholar]
  5. Case D. C., Jr, Lee D. J., 3rd, Clarkson B. D. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med. 1977 Dec;63(6):897–903. doi: 10.1016/0002-9343(77)90543-5. [DOI] [PubMed] [Google Scholar]
  6. Cooper E. H., Forbes M. A., Crockson R. A., MacLennan I. C. Proximal renal tubular function in myelomatosis: observations in the fourth Medical Research Council trial. J Clin Pathol. 1984 Aug;37(8):852–858. doi: 10.1136/jcp.37.8.852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cornwell G. G., 3rd, Pajak T. F., Kochwa S., McIntyre O. R., Glowienka L. P., Brunner K., Rafla S., Silver R. T., Cooper M. R., Henderson E. Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. Cancer. 1982 Nov 1;50(9):1669–1675. doi: 10.1002/1097-0142(19821101)50:9<1669::aid-cncr2820500902>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  8. Hokanson J. A., Brown B. W., Thompson J. R., Drewinko B., Alexanian R. Tumor growth patterns in multiple myeloma. Cancer. 1977 Mar;39(3):1077–1084. doi: 10.1002/1097-0142(197703)39:3<1077::aid-cncr2820390311>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  9. Lee B. J., Sahakian G., Clarkson B. D., Krakoff I. H. Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU. Cancer. 1974 Feb;33(2):533–538. doi: 10.1002/1097-0142(197402)33:2<533::aid-cncr2820330231>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  10. Paccagnella A., Cartei G., Fosser V., Salvagno L., Bolzonella S., Chiarion Sileni V., Fiorentino M. V. Treatment of multiple myeloma with M-2 protocol and without maintenance therapy. Eur J Cancer Clin Oncol. 1983 Oct;19(10):1345–1351. doi: 10.1016/0277-5379(93)90002-m. [DOI] [PubMed] [Google Scholar]
  11. Salmon S. E. Expansion of the growth fraction in multiple myeloma with alkylating agents. Blood. 1975 Jan;45(1):119–129. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES